In section Market Quotes
Teva Pharmaceutical Industries is targeting mid-single-digit revenue growth from 2026 to 2030, with new medicines expected to drive expansion. The company also aims to generate $6 billion to $7 billion in annual revenue from innovative medicines by 2030, it said Wednesday.
Revenue from Teva’s innovative medicines has more than doubled since the company introduced a new growth strategy in 2023. Key products include Austedo, Ajovy and Uzedy; Teva has also recently launched Weltruza.
The company expects growth to continue as it advances its pipeline. Teva said it has seven late-stage pipeline assets with high-value potential, while its innovative pipeline has expanded to ten programs.
“Our R&D engine and commercial excellence are designed to translate proven science into new medicines, with the potential for one new launch annually through 2030,” Chief Executive Richard Francis said.
Comments (0)
No comments yet. Be the first!